CSIMarket Company Name, Ticker, Suppliers, else..
 
Moleculin Biotech Inc   (NASDAQ: MBRX)
 

Moleculin Biotech Inc's Suppliers Performance

MBRX's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
MBRX Costs vs Sales of Suppliers Growth

• More on MBRX Suppliers






Moleculin Biotech Inc's Comment on Supply Chain


The company does not own or operate manufacturing facilities for active pharmaceutical ingredients (API) or final drug products. It relies on third-party contract manufacturers for all API manufacturing and drug product formulation related to clinical development and potential commercial production. For its lead product candidate, Annamycin, the company uses one contract manufacturer for API supply and a separate contract manufacturer for final drug product formulation. Manufacturing agreements are established with these third-party manufacturers to supply API and drug product for clinical trials. The company ensures that contract manufacturers comply with current Good Manufacturing Practice (cGMP) regulations and other regulatory standards. It provides manufacturing forecasts in advance to maintain adequate supply and coordinates production schedules with clinical development timelines. The company recognizes potential competition for contract manufacturers capable of producing its product candidates under cGMP regulations.

Moleculin Biotech Inc's Comment on Supply Chain


The company does not own or operate manufacturing facilities for active pharmaceutical ingredients (API) or final drug products. It relies on third-party contract manufacturers for all API manufacturing and drug product formulation related to clinical development and potential commercial production. For its lead product candidate, Annamycin, the company uses one contract manufacturer for API supply and a separate contract manufacturer for final drug product formulation. Manufacturing agreements are established with these third-party manufacturers to supply API and drug product for clinical trials. The company ensures that contract manufacturers comply with current Good Manufacturing Practice (cGMP) regulations and other regulatory standards. It provides manufacturing forecasts in advance to maintain adequate supply and coordinates production schedules with clinical development timelines. The company recognizes potential competition for contract manufacturers capable of producing its product candidates under cGMP regulations.







MBRX's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Moleculin Biotech Inc 3.21 0.00 -42.16 52
SUBTOTAL 0.00 0.00 0.00 -


Sources: Moleculin Biotech Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Moleculin Biotech Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.